Kang, Joon Ho http://orcid.org/0000-0003-4165-7538
Katsikis, Georgios http://orcid.org/0000-0003-3239-4924
Li, Zhaoqi
Sapp, Kiera M. http://orcid.org/0000-0002-5523-1223
Stockslager, Max A.
Lim, Daniel
Vander Heiden, Matthew G. http://orcid.org/0000-0002-6702-4192
Yaffe, Michael B. http://orcid.org/0000-0002-9547-3251
Manalis, Scott R. http://orcid.org/0000-0001-5223-9433
Miettinen, Teemu P. http://orcid.org/0000-0002-5975-200X
Funding for this research was provided by:
Samsung
J.H.K. was supperted by Samsung Scholarship.
U.S. Department of Health & Human Services | National Institutes of Health (R35-CA242379, R01-CA201276, R01-GM104047, R35-ES028374)
U.S. Department of Health & Human Services | National Institutes of Health
M.G.V.H. also acknowledges support from the Lustgarten Foundation, the Ludwig Center at MIT, and a faculty scholars award from HHMI.
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
M.B.Y. received funding from the MIT Center for Precision Cancer Medicine.
S.R.M. recieved funding from the Koch Institute Frontier Research Program through the Kathy and Curt Marble Cancer Research Fund.
Wellcome Trust (110275/Z/15/Z)
Article History
Received: 14 October 2019
Accepted: 10 September 2020
First Online: 5 October 2020
Competing interests
: S.R.M. is a co-founder of Travera and Affinity Biosensors, which develops techniques relevant to the research presented. M.G.V.H. is on the scientific advisory board of Agios Pharmaceuticals, Aeglea Biotherapeutics, iTEOS therapeutics, and Auron Therapeutics. The remaining authors declare no competing interests.